Medical Communications

Showing 15 posts of 6408 posts found.

ARTBIO expands board and establishes technical advisory board

August 11, 2025 Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …
pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025 Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …
az_vaccine

Rollout of world-first gonorrhoea vaccine programme begins under NHS

August 8, 2025 Medical Communications 10 Year Health Plan, Genito-Urinary system, Infections and infestations, NHS, gonorrhoea, sexual health, sexually transmitted infections, vaccination

From 4 August, sexual health clinics in England have been able to offer a free vaccine – the 4CMenB vaccine …
drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025 Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025 Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025 Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025 Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …

Five Facts about sleep and mental health

August 3, 2025 Medical Communications Five Facts, Psychiatry, insomnia, mental health, sleep, sleep disorders, sleep health

1 Rapid Eye Movement (REM) sleep enhances creative thinking and helps the brain form connections between ideas, supporting mental wellbeing …

Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer

August 1, 2025 Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer

Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025 Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025 Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis

July 21, 2025 Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease

Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …

LDC strengthens healthcare focus with appointment of Amit Thaper as investment director

July 21, 2025 Business Services, Industry Associations, Research and Development Corporate, Inicio Health, Investment Director, LDC, RDi

LDC, the private equity arm of Lloyds Banking Group, has strengthened its healthcare expertise with the appointment of Amit Thaper …
The Gateway to Local Adoption Series

Latest content